Your browser doesn't support javascript.
loading
Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets.
Stephan, Pierre; Perrot, Jimmy; Voisin, Allison; Barbery, Maud; Andrieu, Thibault; Grimont, Maxime; Caramel, Julie; Bardou, Mathilde; Tondeur, Garance; Missiaglia, Edoardo; Gaulard, Philippe; Lemmonier, François; De Leval, Laurence; Bachy, Emmanuel; Sujobert, Pierre; Genestier, Laurent; Traverse-Glehen, Alexandra; Grinberg-Bleyer, Yenkel.
Afiliación
  • Stephan P; Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon.
  • Perrot J; Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite.
  • Voisin A; Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon.
  • Barbery M; Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon.
  • Andrieu T; Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon.
  • Grimont M; Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon.
  • Caramel J; Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon.
  • Bardou M; Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite.
  • Tondeur G; Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite.
  • Missiaglia E; Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne.
  • Gaulard P; AP-HP, Henri Mondor Hospital, Pathology Department, Créteil, France; University Paris Est Créteil, INSERM, IMRB, Créteil.
  • Lemmonier F; AP-HP, Henri Mondor Hospital, Pathology Department, Créteil, France; University Paris Est Créteil, INSERM, IMRB, Créteil.
  • De Leval L; Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne.
  • Bachy E; Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite, France; Centre International de Recherche en Infectiologie (CIRI), Team Lymphoma Immuno-Biology, UMR INSERM U1111, CNRS 5308, Université Claude Bernard Lyon I, ENS de Lyon, Lyon.
  • Sujobert P; Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite, France; Centre International de Recherche en Infectiologie (CIRI), Team Lymphoma Immuno-Biology, UMR INSERM U1111, CNRS 5308, Université Claude Bernard Lyon I, ENS de Lyon, Lyon.
  • Genestier L; Centre International de Recherche en Infectiologie (CIRI), Team Lymphoma Immuno-Biology, UMR INSERM U1111, CNRS 5308, Université Claude Bernard Lyon I, ENS de Lyon, Lyon.
  • Traverse-Glehen A; Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite.
  • Grinberg-Bleyer Y; Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon. yenkel.grinberg-bleyer@inserm.fr.
Haematologica ; 2024 May 30.
Article en En | MEDLINE | ID: mdl-38813724
ABSTRACT
Whereas immunotherapies have revolutionized the treatment of different solid and hematological cancers, their efficacy in nodal peripheral T-cell lymphomas (PTCLs) is limited, due to a lack of understanding of the immune response they trigger. To fully characterize the immune tumor microenvironment (TME) of PTCLs, we performed spectral flow cytometry analyses on 11 angioimmunoblastic T-cell lymphomas (AITL), 7 PTCL, not otherwise specified (PTCL, NOS) lymph node samples, and 10 non-tumoral control samples. The PTCL TME contained a larger proportion of regulatory T cells and exhausted CD8+ T cells, with enriched expression of druggable immune checkpoints. Interestingly, CD39 expression was up-regulated at the surface of most immune cells, and a multi-immunofluorescence analyses on a retrospective cohort of 43 AITL patients demonstrated a significant association between high CD39 expression by T cells and poor patient prognosis. Together, our study unravels the complex TME of nodal PTCLs, identifies targetable immune checkpoints, and highlights CD39 as a novel prognostic factor.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Haematologica Año: 2024 Tipo del documento: Article Pais de publicación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Haematologica Año: 2024 Tipo del documento: Article Pais de publicación: Italia